Non-medical  switch  from  originator  to  biosimilar in fliximab  in  patients  with  inflammatory  arthritis: impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry

B Glintborg; T Kringelbach; E Høgdall; I J Sørensen; D V Jensen; A G Loft; O Hendricks; I M J Hansen; N Bolstad; D J Warren; J Gehin; G Goll; K L Grøn; G Eng; C Enevold; C H Nielsen; J S Johansen; M L Hetland

doi:10.1080/03009742.2016.1207299

Non-medical switch from originator to biosimilar in fliximab in patients with inflammatory arthritis: impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry

B Glintborg, T Kringelbach, E Høgdall, I J Sørensen, D V Jensen, A G Loft, O Hendricks, I M J Hansen, N Bolstad, D J Warren, J Gehin, G Goll, K L Grøn, G Eng, C Enevold, C H Nielsen, J S Johansen, M L Hetland

Department of Clinical Medicine

Original language	English
Article number	OP10
Journal	Scandinavian Journal of Rheumatology
Volume	45
Issue number	sup128
Number of pages	2
ISSN	0300-9742
DOIs	https://doi.org/10.1080/03009742.2016.1207299
Publication status	Published - 2016

Access to Document

10.1080/03009742.2016.1207299

Cite this

Glintborg, B., Kringelbach, T., Høgdall, E., Sørensen, I. J., Jensen, D. V., Loft, A. G., Hendricks, O., Hansen, I. M. J., Bolstad, N., Warren, D. J., Gehin, J., Goll, G., Grøn, K. L., Eng, G., Enevold, C., Nielsen, C. H., Johansen, J. S., & Hetland, M. L. (2016). Non-medical switch from originator to biosimilar in fliximab in patients with inflammatory arthritis: impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry. Scandinavian Journal of Rheumatology, 45(sup128), [OP10]. https://doi.org/10.1080/03009742.2016.1207299

Non-medical switch from originator to biosimilar in fliximab in patients with inflammatory arthritis : impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry. / Glintborg, B; Kringelbach, T; Høgdall, E et al.

In: Scandinavian Journal of Rheumatology, Vol. 45, No. sup128, OP10, 2016.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Glintborg, B, Kringelbach, T, Høgdall, E, Sørensen, IJ, Jensen, DV, Loft, AG, Hendricks, O, Hansen, IMJ, Bolstad, N, Warren, DJ, Gehin, J, Goll, G, Grøn, KL, Eng, G, Enevold, C, Nielsen, CH, Johansen, JS & Hetland, ML 2016, 'Non-medical switch from originator to biosimilar in fliximab in patients with inflammatory arthritis: impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry', Scandinavian Journal of Rheumatology, vol. 45, no. sup128, OP10. https://doi.org/10.1080/03009742.2016.1207299

Glintborg B, Kringelbach T, Høgdall E, Sørensen IJ, Jensen DV, Loft AG et al. Non-medical switch from originator to biosimilar in fliximab in patients with inflammatory arthritis: impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry. Scandinavian Journal of Rheumatology. 2016;45(sup128):OP10. doi: 10.1080/03009742.2016.1207299

@article{009d7543b5b84991a3c9d0680179cd00,

title = "Non-medical switch from originator to biosimilar in fliximab in patients with inflammatory arthritis: impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry",

author = "B Glintborg and T Kringelbach and E H{\o}gdall and S{\o}rensen, {I J} and Jensen, {D V} and Loft, {A G} and O Hendricks and Hansen, {I M J} and N Bolstad and Warren, {D J} and J Gehin and G Goll and Gr{\o}n, {K L} and G Eng and C Enevold and Nielsen, {C H} and Johansen, {J S} and Hetland, {M L}",

year = "2016",

doi = "10.1080/03009742.2016.1207299",

language = "English",

volume = "45",

journal = "Scandinavian Journal of Rheumatology",

issn = "0300-9742",

publisher = "Taylor & Francis",

number = "sup128",

}

TY - ABST

T1 - Non-medical switch from originator to biosimilar in fliximab in patients with inflammatory arthritis

T2 - impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry

AU - Glintborg, B

AU - Kringelbach, T

AU - Høgdall, E

AU - Sørensen, I J

AU - Jensen, D V

AU - Loft, A G

AU - Hendricks, O

AU - Hansen, I M J

AU - Bolstad, N

AU - Warren, D J

AU - Gehin, J

AU - Goll, G

AU - Grøn, K L

AU - Eng, G

AU - Enevold, C

AU - Nielsen, C H

AU - Johansen, J S

AU - Hetland, M L

PY - 2016

Y1 - 2016

U2 - 10.1080/03009742.2016.1207299

DO - 10.1080/03009742.2016.1207299

M3 - Conference abstract in journal

SN - 0300-9742

VL - 45

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

IS - sup128

M1 - OP10

ER -